Robert Essner - 04 Jun 2021 Form 4 Insider Report for Organon & Co. (OGN)

Reporting relationship: Director
Issuer ticker: OGN
Reported as of: 04 Jun 2021
Net transaction value: +$316,231
SEC form: 4
Accepted by SEC: 08 Jun 2021, 20:36:39 UTC
Prior SEC filing: 02 Jun 2021
Next SEC filing: 14 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Faye C. Brown, as Attorney-in-Fact for Robert Essner

Key filing fact

Robert Essner filed Form 4 for Organon & Co. (OGN) on 08 Jun 2021.

Key facts

This page summarizes Robert Essner's Form 4 filing for Organon & Co. (OGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2021, 20:36.

Change

Previous filing in this sequence was filed on 02 Jun 2021.
Current net transaction value: +$316,231.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGN transaction Derivative

Phantom Stock

Award

Transaction value: $316,231
Shares: +8,772
Change %
Price: $36.05
Shares after: 8,772
Date: 04 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,772
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1-for-1

Footnote F2

Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the separation of Organon & Co. ("Organon") from Merck & Co., Inc. (the "Separation"), which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,223 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases.